You just read:

Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology

News provided by

Daiichi Sankyo Company, Limited

Dec 11, 2017, 17:00 ET